The novel reactive aldehyde species (RASP) inhibitor ADX-102, also known as Reproxalap, was recently reported to be safe and effective for the treatment of dry eye disease (DED) [40,41] as well as ocular inflammatory conditions such as noninfectious anterior uveitis and allergic conjunctivitis [15]. Here, HHAT is linked to anterior uveitis.